GLP-1 receptor agonist confer target organ protection in type 2 diabetes

Diabetes and Metabolism

Volumn 43, Issue , 2017, Pages 2S1-2S2

  Bonnet, Fabrice ^a  

^a UNIVERSITÉ DE RENNES 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR;

CARDIOVASCULAR EFFECT; EDITORIAL; FOLLOW UP; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIMARY PREVENTION; STOMACH EMPTYING; TARGET ORGAN; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION; AGONISTS;

DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 85017574447     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/S1262-3636(17)30066-6     Document Type: Editorial

References (16)

1. [1] Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab 2016.
2. [2] Alatorre C, Fernandez Lando L, Yu M, Brown K, Montejano L, Juneau P, et al. treatment patterns in patients with type 2 diabetes mellitus treated with GLP-1 receptor agonists: Higher adherence and persistence with dulaglutide compared to exenatide qw and liraglutide. Diabetes Obes Metab 2017.
3. [3] Cariou, B., Fontaine, P., Eschwege, E., Lievre, M., Gouet, D., Huet, D., et al. Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. Diabetes Metab 41 (2015), 116–125.
4. [4] Scheen, A.J., Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis. Diabetes Metab 42 (2016), 71–76.
5. [5] Lingvay, I., Perez Manghi, F., Garcia-Hernandez, P., Norwood, P., Lehmann, L., Tarp-Johansen, M.J., et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: The DUAL V randomized clinical trial. JAMA 315 (2016), 898–907.
6. [6] Porcellati, F., Lucidi, P., Bolli, G.B., Fanelli, C.G., GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials. Diabetes Metab 41:6Suppl1 (2015), 6S16–6S20.
7. [7] Darmon, P., Raccah, D., Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?. Diabetes Metab 41:6Suppl1 (2015), 6S21–6S27.
8. [8] Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
9. [9] Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jodar, E., Leiter, L.A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375 (2016), 1834–1844.
10. [10] Kramer CK, Zinman B, Choi H, Connelly PW, Retnakaran R. Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes. Diabetes Obes Metab 2017.
11. [11] Petit JM, Cercueil JP, Loffroy R, Denimal D, Bouillet B, Fourmont C, et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study. J Clin Endocrinol Metab 2016:jc20162775.
12. [12] Hu, Y., Liu, J., Zhang, H., Xu, Y., Hong, T., Wang, G., Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Metab 42 (2016), 358–363.
13. [13] Scheen, A.J., Esser, N., Paquot, N., Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control. Diabetes Metab 41 (2015), 183–194.
14. [14] Faghihi-Kashani, S., Bonnet, F., Hafezi-Nejad, N., Heidari, B., Aghajani Nargesi, A., Sheikhbahaei, S., et al. Fasting hyperinsulinaemia and 2-h glycaemia predict coronary heart disease in patients with type 2 diabetes. Diabetes Metab 42 (2016), 55–61.
15. [15] Storgaard H, Cold F, Gluud LL, Vilsboll T, Knop FK. Glucagon-like peptide-1 agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab 2017.
16. [16] Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Kober, L.V., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373 (2015), 2247–2257.